Literature DB >> 29313128

[Surgical strategies for non-metastatic adrenocortical carcinoma].

N Rayes1, M Quinkler2, T Denecke3.   

Abstract

Adrenocortical carcinomas (ACC) are rare but highly aggressive tumors. It is very difficult to differentiate small locally limited ACCs from benign adenomas. A spontaneous density >10 Hounsfield units in non-enhanced CT scan and a slow washout after contrast injection are suspicious of malignancy but with a low specificity. Preoperatively, a hormonal work-up is mandatory for all adrenal tumors. Each patient should be discussed in an interdisciplinary board. For non-metastatic ACCs (ENSAT stages I-III) radical resection is the treatment of choice. R0-resection and avoiding violation of the tumor capsule are the most important prognostic factors for long-term survival. Although discrepant reports regarding the benefits of lymphadenectomy have been published, lymph node dissection at least in the periadrenal area and in the renal hilum (optional extension to paraaortal and paracaval nodes) should be performed in the case of lymph node involvement. The role of prophylactic lymphadenectomy needs to be analyzed in further studies. The gold standard remains the open approach but minimally invasive procedures are also an option, especially in stage I-II tumors, if the principles of oncological surgery are respected. In this case, long-term survival rates are comparable. As local recurrence rates are lower and time to local recurrence is longer in patients who are operated on at a dedicated center (>10 adrenalectomies/year), adrenalectomy for ACC should be performed by an experienced surgeon.

Entities:  

Keywords:  Incidentaloma; Lymphadenectomy; Minimally invasive adrenalectomy; Open adrenalectomy; Preoperative diagnostics

Mesh:

Year:  2018        PMID: 29313128     DOI: 10.1007/s00104-017-0582-1

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  30 in total

1.  Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  A Berruti; E Baudin; H Gelderblom; H R Haak; F Porpiglia; M Fassnacht; G Pentheroudakis
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

2.  Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients.

Authors:  David Brix; Bruno Allolio; Wiebke Fenske; Ayman Agha; Henning Dralle; Christian Jurowich; Peter Langer; Thomas Mussack; Christoph Nies; Hubertus Riedmiller; Martin Spahn; Dirk Weismann; Stefanie Hahner; Martin Fassnacht
Journal:  Eur Urol       Date:  2010-06-22       Impact factor: 20.096

3.  Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit?

Authors:  Jon M Gerry; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason D Prescott; Tracy S Wang; Jason A Glenn; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Ioannis Hatzaras; Rivfka Shenoy; Timothy M Pawlik; Jeffrey A Norton; George A Poultsides
Journal:  Ann Surg Oncol       Date:  2016-09-02       Impact factor: 5.344

4.  Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.

Authors:  Tarek Ezzat Abdel-Aziz; Parameswaran Rajeev; Greg Sadler; Andrew Weaver; Radu Mihai
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

5.  Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.

Authors:  P Icard; P Goudet; C Charpenay; B Andreassian; B Carnaille; Y Chapuis; P Cougard; J F Henry; C Proye
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

6.  Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection.

Authors:  Felix Beuschlein; Jens Weigel; Wolfgang Saeger; Matthias Kroiss; Vanessa Wild; Fulvia Daffara; Rosella Libé; Arianna Ardito; Abir Al Ghuzlan; Marcus Quinkler; Andrea Oßwald; Cristina L Ronchi; Ronald de Krijger; Richard A Feelders; Jens Waldmann; Holger S Willenberg; Timo Deutschbein; Anthony Stell; Martin Reincke; Mauro Papotti; Eric Baudin; Frédérique Tissier; Harm R Haak; Paola Loli; Massimo Terzolo; Bruno Allolio; Hans-Helge Müller; Martin Fassnacht
Journal:  J Clin Endocrinol Metab       Date:  2015-01-05       Impact factor: 5.958

7.  Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.

Authors:  Gwenaelle Abiven; Joel Coste; Lionel Groussin; Philippe Anract; Frédérique Tissier; Paul Legmann; Bertrand Dousset; Xavier Bertagna; Jérôme Bertherat
Journal:  J Clin Endocrinol Metab       Date:  2006-05-02       Impact factor: 5.958

8.  Open versus endoscopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: results of a multiinstitutional Italian survey.

Authors:  Celestino Pio Lombardi; Marco Raffaelli; Carmela De Crea; Marco Boniardi; Giorgio De Toma; Luigi Antonio Marzano; Paolo Miccoli; Francesco Minni; Mario Morino; Maria Rosa Pelizzo; Andrea Pietrabissa; Andrea Renda; Andrea Valeri; Rocco Bellantone
Journal:  Surgery       Date:  2012-10-13       Impact factor: 3.982

Review 9.  Clinical review: Adrenocortical carcinoma: clinical update.

Authors:  Bruno Allolio; Martin Fassnacht
Journal:  J Clin Endocrinol Metab       Date:  2006-03-21       Impact factor: 5.958

10.  Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.

Authors:  Martin Fassnacht; Wiebke Arlt; Irina Bancos; Henning Dralle; John Newell-Price; Anju Sahdev; Antoine Tabarin; Massimo Terzolo; Stylianos Tsagarakis; Olaf M Dekkers
Journal:  Eur J Endocrinol       Date:  2016-08       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.